Growing Preferences towards Analog-based Drug Discovery

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Computational Biology

Background:

• Rising antimicrobial resistance in pathogens necessitates novel therapeutic agents.
• Existing drugs are becoming ineffective due to microbial resistance mechanisms.
• Development of new molecules with improved efficacy against resistant strains is critical.

Purpose of the Study:

• To review recent advancements in Analog-Based Drug Design (ABDD) for antimicrobial drug development.
• To highlight the utility of ABDD in creating cost-effective drug-like molecules.
• To explore the role of in silico tools in accelerating the design and screening of novel analogs.

Main Methods:

• Analog-Based Drug Design (ABDD) focusing on structural and pharmacological similarities to existing drugs.
• Utilizing scaffolds of clinically approved but currently ineffective drugs.
• Employing in silico tools for computational screening and analog design.

Main Results:

• ABDD enables the development of new drug-like molecules with potentially lower market costs.
• This approach leverages existing drug scaffolds to overcome pathogen resistance.
• In silico screening aids in identifying promising analogs for further validation.

Conclusions:

• ABDD is a viable strategy for developing novel antifungal and antibacterial agents.
• In silico methods enhance the efficiency of designing and screening potential drug candidates.
• This approach aims to reduce failure rates in in vitro validation and accelerate the discovery of effective antimicrobials.